Written Authority Required Drugs

Some Pharmaceutical Benefits Scheme (PBS) subsidised medicines require written authority approval from us before they can be prescribed.

This is due to their clinical use or other special features.

This includes a number of Complex Authority Required (CAR) drugs. These medicines will not be PBS subsidised without authority approval and retrospective approval cannot be granted.

Applying

Applying for authority approval

Health Professional Online Services (HPOS):

To apply for approval to prescribe a written authority required drug through HPOS, you must upload the completed and signed PBS authority application form, supporting documentation and authority prescription form(s).

When approved, prescribers can access the authority approval number through HPOS and must record it on the authority prescription form. Prescribers should also record the item code on the authority prescription form.

Mail:

To apply for approval to prescribe a written authority required drug via mail, you must post the completed and signed PBS authority application form, supporting documentation and authority prescription form(s).

When approved, the authority prescription form is stamped with CAR approval and returned by mail to the provider or patient as indicated on the form.

Phone:

Where authority applications for balance of supply or continuing treatment can be made by phone, you must call the PBS Complex Drugs Programs enquiry line.

When approved, prescribers must record the authority approval number provided by us on the authority prescription form. Phone authority approval numbers start with Z, CARZ or TRZZ and are followed by 4 digits and 2 letters. For example, Z1234AB or CARZ1234AB or TRZZ1234AB.

Find out more in Health professionals contact information.

Hospital authority form

To prescribe CAR Highly Specialised Drugs (HSDs) in a non-reform public hospital approved to supply HSDs, prescribers must use the Non PBS Reform Public Hospital Highly Specialised Drugs and Trastuzumab Only Authority Prescription Form (PB054).

To prescribe CAR HSDs in a public hospital participating in the pharmaceutical reforms, the prescriber can use the Public Hospital Prescription form.

To prescribe CAR HSDs in a private hospital, prescribers can use their own personalised PBS prescription pads.

Drug, program or condition

Acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib mesilate and ponatinib for patients with acute lymphoblastic leukaemia (ALL).

Read more about acute lymphoblastic leukaemia

Acromegaly

The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

Read more about acromegaly

Alzheimer's disease

The PBS subsidises medicines for eligible patients with Alzheimer's disease.

Read more about Alzheimer's disease

Ankylosing spondylitis

The PBS subsidises biological agents for patients with active ankylosing spondylitis.

Read more about ankylosing spondylitis

Atypical haemolytic uraemic syndrome

The PBS subsidises eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS).

Read more about atypical haemolytic uraemic syndrome

Azacitidine

The PBS subsidises azacitidine for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Read more about azacitidine

BH4 deficiency

The PBS subsidises sapropterin for patients with tetrahydrobiopterin (BH4) deficiency.

Read more about BH4 deficiency

Chronic lymphocytic leukaemia

The PBS subsidises idelalisib and obinutuzumab for patients with chronic lymphocytic leukaemia (CLL).

Read more about chronic lymphocytic leukaemia

Chronic myeloid leukaemia

The PBS subsidises tyrosine kinase inhibitor (TKI) agents for patients with chronic myeloid leukaemia (CML).

Read more about chronic myeloid leukaemia

Chronic thromboembolic pulmonary hypertension

The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension.

Read more about chronic thromboembolic pulmonary hypertension

Crohn's disease - Adult patient

The PBS subsidises biological disease modifying drugs for adult patients with severe Crohn's disease.

Read more about Crohn's disease - adult patient

Crohn's disease - Paediatric patient

The PBS subsidises TNF alfa antagonists for paediatric patients with Crohn's disease.

Read more about Crohn's disease - paediatric patient

Cutaneous T-cell lymphoma

The PBS subsidises vorinostat for patients with cutaneous T-cell lymphoma (CTCL).

Read more about cutaneous T-cell lymphoma (CTCL)

Cystic fibrosis

The PBS subsidises ivacaftor for patients aged 2 years or older with cystic fibrosis.

Read more about cystic fibrosis

Diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).

Read more about diabetic macular oedema

Early breast cancer

The PBS subsidises trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) positive early breast cancer or HER2 positive locally advanced breast cancer.

Read more about early breast cancer

Eosinophilic asthma

The PBS subsidises mepolizumab for patients with uncontrolled severe eosinophilic asthma.

Read more about severe eosinophilic asthma

Familial homozygous hypercholesterolaemia

The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.

Read more about familial homozygous hypercholesterolaemia

Fistulising Crohn's disease

The PBS subsidises tumour necrosis factor alfa antagonists for patients with complex refractory fistulising Crohn's disease.

Read more about fistulising Crohn's disease

Gastrointestinal stromal tumour - adjuvant

The PBS subsidises imatinib mesilate for patients with resected primary gastrointestinal stromal tumour (GIST) with high risk of recurrence.

Read more about GIST - adjuvant

Gastrointestinal stromal tumour - metastatic or unresectable

The PBS subsidises imatinib mesilate for patients with metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).

Read more about GIST - metastatic or unresectable

Gastrointestinal stromal tumour - sunitinib malate

The PBS subsidises sunitinib malate for patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).

Read more about GIST - sunitinib malate

Growth Hormone Program

The Growth Hormone Program provides subsidised PBS treatment to eligible children under a number of categories.

Read more about Growth Hormone Program

Hidradenitis Suppurativa

The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa (HS).

Read more about hidradenitis suppurativa

Hodgkin lymphoma

The PBS subsidises brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.

Read more about Hodgkin lymphoma

Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

Read more about Idiopathic pulmonary fibrosis

Idiopathic thrombocytopenic purpura

The PBS subsidises eltrombopag and romiplostim for patients with severe chronic immune idiopathic thrombocytopenic purpura.

Read more about idiopathic thrombocytopenic purpura

Juvenile idiopathic arthritis

The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active juvenile idiopathic arthritis.

Read more about juvenile idiopathic arthritis

Metastatic or locally advanced basal cell carcinoma

The PBS subsidises vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Read more about metastatic or locally advanced basal cell carcinoma

Metastatic breast cancer

The PBS subsidises pertuzumab, lapatinib, trastuzumab emtansine and trastuzumab for patients with metastatic breast cancer.

Read more about metastatic breast cancer

Metastatic stage IV HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

The PBS subsidises trastuzumab for patients with metastatic stage IV HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.

Read more about Metastatic stage IV HER2 positive adenocarcinoma of the stomach

Multiple myeloma - bortezomib, lenalidomide and pomalidomide

The PBS subsidises bortezomib, lenalidomide and pomalidomide for patients with multiple myeloma.

Read more about multiple myeloma - bortezomib, lenalidomide and pomalidomide

Myelodysplastic syndrome

The PBS subsidises lenalidomide for patients with myelodysplastic syndrome classified as low risk or Intermediate-1.

Read more about myelodysplastic syndrome

Myelofibrosis

The PBS subsidises ruxolitinib for patients with myelofibrosis.

Read more about myelofibrosis

Narcolepsy

The PBS subsidises modafinil and armodafinil for patients with narcolepsy.

Read more about narcolepsy

Non-small cell lung cancer

The PBS subsidises crizotinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Read more about non-small cell lung cancer

Pulmonary arterial hypertension

The PBS subsidises a range of medicines for patients with primary pulmonary and pulmonary arterial hypertension.

Read more about primary pulmonary and pulmonary arterial hypertension

Psoriatic arthritis

The PBS subsidises biological agents for patients with severe active psoriatic arthritis.

Read more about psoriatic arthritis

Rare diseases

The PBS subsidises imatinib mesilate for patients with rare diseases.

Read more about rare diseases

Refractory follicular B-cell non-Hodgkin’s lymphoma

The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Read more about refractory follicular B-cell non-Hodgkin’s lymphoma

Retinal vein occlusion

The PBS subsidises aflibercept and ranibizumab for patients with branched retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), with macular oedema.

Read more about retinal vein occlusion

Rheumatoid arthritis

The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active rheumatoid arthritis.

Read more about rheumatoid arthritis

Severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis

The PBS subsidises rituximab for patients with severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis.

Read more on this condition

Severe allergic asthma - adolescent and adult patients

The PBS subsidises omalizumab for patients aged 12 years or older with uncontrolled severe allergic asthma.

Read more about severe allergic asthma - adolescent and adult patients

Severe allergic asthma - paediatric patient

The PBS subsidises omalizumab for paediatric patients with uncontrolled severe allergic asthma.

Read more about severe allergic asthma - paediatric patient

Severe chronic plaque psoriasis

The PBS subsidises biological agents for adult patients with severe chronic plaque psoriasis.

Read more about severe chronic plaque psoriasis

Severe chronic plaque psoriasis for patients under 18 years

The PBS subsidises etanercept for patients under 18 years with severe chronic plaque psoriasis.

Read more about severe chronic plaque psoriasis for patients under 18 years

Severe chronic spontaneous urticaria

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

Read more about severe chronic spontaneous urticaria

Small lymphocytic lymphoma

The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

Read more about small lymphocytic lymphoma

Subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.

Read more about subfoveal choroidal neovascularisation

Systemic anaplastic large cell lymphoma

The PBS subsidises brentuximab vedotin for eligible patients with systemic anaplastic large cell lymphoma.

Read more about systemic anaplastic large cell lymphoma

Systemic juvenile idiopathic arthritis

The PBS subsidises tocilizumab for patients with systemic juvenile idiopathic arthritis.

Read more about systemic juvenile idiopathic arthritis

Ulcerative colitis

The PBS subsidises adalimumab, infliximab and vedolizumab (adults only) for patients with moderate to severe ulcerative colitis.

Read more about ulcerative colitis

Related subjects

Page last updated: 1 October 2017